We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Arix Bioscience Plc | LSE:ARIX | London | Ordinary Share | GB00BD045071 | ORD 0.001P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 142.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMARIX ARIX BIOSCIENCE PLC Director/PDMR Shareholding LONDON, 13 March 2020: Arix Bioscience plc (LSE:ARIX) ("Arix"), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces a conditional share award to Jonathan Peacock, Chairman, relating to his service in 2019 as an Executive Director. The award is subject to performance conditions over a three year assessment period, consistent with the awards made to other Executive Directors in 2019, as detailed on page 70 of the Annual Report and Accounts. PDMR DEALING NOTIFICATION Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 1 Details of the person discharging managerial responsibilities / person closely associated a) Name Jonathan Peacock 2 Reason for the notification a) Position / status Chairman b) Initial Initial Notification notification / Amendment 3 Details of issuer a) Name Arix Bioscience plc b) LEI 213800OVT3AHQCXNIX43 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of Ordinary Shares of Arix Bioscience plc the financial instrument, type of instrument Identification GB00BD045071 code b) Nature of the Conditional share award transaction c) Price(s) and Price(s) Volume(s) volume(s) Nil 231,348 d) Aggregated Aggregated price Aggregated volume information N/A (single N/A (single transaction) transaction) e) Date of the 12 March 2020 transaction f) Place of the Outside a trading venue transaction For further information: Robert Lyne Chief Operating Officer and General Counsel +44 (0)207 290 1050 - Ends - END
(END) Dow Jones Newswires
March 16, 2020 03:00 ET (07:00 GMT)
1 Year Arix Bioscience Chart |
1 Month Arix Bioscience Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions